Crome P, Curl B, Holt D, Volans G N, Bennett P N, Cole D S
Hum Toxicol. 1985 Jul;4(4):391-9. doi: 10.1177/096032718500400405.
The potential for a pharmacokinetic interaction between digoxin and cimetidine was investigated in a series of studies. In a single-dose cross-over study in healthy volunteer subjects cimetidine increased the area under the plasma digoxin concentration curve and the peak plasma digoxin concentration. In a repeated-dose study in healthy volunteer subjects taking digoxin 0.25 mg daily, co-administration of cimetidine resulted in an average increase in plasma digoxin concentration of 0.15 ng/ml. In a repeated-dose study in healthy volunteer subjects taking digoxin 0.5 mg daily, co-administration of cimetidine resulted in an average increase in plasma digoxin concentration of 0.19 ng/ml. In a repeated-dose study in patients receiving long-term digoxin therapy for atrial fibrillation co-administration of cimetidine had no significant effect on plasma digoxin concentrations. We have shown that co-administration of cimetidine and digoxin in volunteer subjects causes a statistically significant but small increase in plasma digoxin concentration but no such increase was found in patients. We conclude that it is doubtful that this interaction is of any clinical significance.
在一系列研究中,对洋地黄毒苷和西咪替丁之间的药代动力学相互作用潜力进行了研究。在一项针对健康志愿者的单剂量交叉研究中,西咪替丁增加了血浆洋地黄毒苷浓度曲线下面积以及血浆洋地黄毒苷峰值浓度。在一项针对每日服用0.25毫克洋地黄毒苷的健康志愿者的重复剂量研究中,西咪替丁的共同给药导致血浆洋地黄毒苷浓度平均增加0.15纳克/毫升。在一项针对每日服用0.5毫克洋地黄毒苷的健康志愿者的重复剂量研究中,西咪替丁的共同给药导致血浆洋地黄毒苷浓度平均增加0.19纳克/毫升。在一项针对接受长期洋地黄毒苷治疗心房颤动的患者的重复剂量研究中,西咪替丁的共同给药对血浆洋地黄毒苷浓度没有显著影响。我们已经表明,在志愿者中,西咪替丁和洋地黄毒苷的共同给药会导致血浆洋地黄毒苷浓度出现统计学上显著但较小的增加,但在患者中未发现这种增加。我们得出结论,这种相互作用是否具有任何临床意义值得怀疑。